RE:RE:RE:RE:The Seeking Alpha article from two years ago Good summary of where we are Hempdoc. Recruitment is for sure the key and as you say:
' We are contending with a strong, concerted effort to direct/divert potential patients towards immunotherapy, & perhaps simply an effort to direct them away from our technology.'
Yes - and even if one of our MSAB members is not positively part of that effort his failure to so much as mention the potential of PDT in a recent overview can only be helpful to our competitors.
Some contrast to his statement when he joined the MSAB in December 2014:
‘Theralase's preclinical Photo Dynamic Compound ("PDC") technology has the potential to revolutionize the treatment of various tumors, especially bladder cancer and moreover their technology has the scientific rigour to advance to commercialization. My role will be to provide the clinical expertise and to work with my fellow MSAB members to develop a clinical protocol for Theralase's trials in the treatment of bladder cancer. …’
Whatever happened to Prof.Kamat???